These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003 [TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib: the first agent approved for myelofibrosis. Verstovsek S Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352 [No Abstract] [Full Text] [Related]
10. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053 [TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib (Jakafi) for myelofibrosis. Med Lett Drugs Ther; 2012 Apr; 54(1387):27-8. PubMed ID: 22469651 [No Abstract] [Full Text] [Related]
12. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. Iurlo A; Cattaneo D; Boiocchi L; Orofino N; Fermo E; Cortelezzi A; Gianelli U Ann Hematol; 2015 Oct; 94(10):1749-51. PubMed ID: 26082334 [No Abstract] [Full Text] [Related]
13. Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Pardanani A Leukemia; 2012 Jul; 26(7):1449-51. PubMed ID: 22285996 [No Abstract] [Full Text] [Related]
14. Ruxolitinib: a new treatment option for myelofibrosis. Ganetsky A Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549 [TBL] [Abstract][Full Text] [Related]
15. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis. Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088 [TBL] [Abstract][Full Text] [Related]
16. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Chen YH; Lee CH; Pei SN Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182 [No Abstract] [Full Text] [Related]
18. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963 [TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Geyer H; Cannon K; Knight E; Fauble V; Camoriano J; Emanuel R; Tibes R; Mesa R Leuk Lymphoma; 2014 Jan; 55(1):195-7. PubMed ID: 23647081 [No Abstract] [Full Text] [Related]